This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Analysts’ Opinions Are Mixed on These Healthcare Stocks: West Pharmaceutical Services (WST), CVRx (CVRX) and AbCellera Biologics (ABCL)

Tipranks - Tipranks - Wed May 13, 6:52AM CDT

Analysts have been eager to weigh in on the Healthcare sector with new ratings on West Pharmaceutical Services (WST), CVRx (CVRX) and AbCellera Biologics (ABCL).

Claim 55% Off TipRanks

West Pharmaceutical Services (WST)

In a report issued on May 7, Kallum Titchmarsh from Morgan Stanley maintained a Hold rating on West Pharmaceutical Services, with a price target of $315.00. The company’s shares closed last Monday at $322.30.

According to TipRanks.com, Titchmarsh is a 1-star analyst with an average return of -0.8% and a 34.3% success rate. Titchmarsh covers the Healthcare sector, focusing on stocks such as Tempus AI, Inc. Class A, Charles River Labs, and Stevanato Group. ;'>

The word on The Street in general, suggests a Strong Buy analyst consensus rating for West Pharmaceutical Services with a $335.00 average price target, a 2.3% upside from current levels. In a report issued on April 24, TipRanks – Anthropic also downgraded the stock to Hold with a $336.00 price target.

See Insiders’ Hot Stocks on TipRanks >>

CVRx (CVRX)

In a report released today, Robbie Marcus from J.P. Morgan reiterated a Sell rating on CVRx, with a price target of $6.00. The company’s shares closed last Monday at $6.92, close to its 52-week low of $6.40.

According to TipRanks.com, Marcus is a 4-star analyst with an average return of 6.7% and a 49.7% success rate. Marcus covers the Healthcare sector, focusing on stocks such as GE Healthcare Technologies Inc, Inspire Medical Systems, and Zimmer Biomet Holdings. ;'>

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for CVRx with a $11.00 average price target, which is a 59.0% upside from current levels. In a report issued on April 30, TipRanks – xAI also downgraded the stock to Sell with a $6.50 price target.

AbCellera Biologics (ABCL)

In a report released today, Debanjana Chatterjee from JonesTrading reiterated a Buy rating on AbCellera Biologics, with a price target of $13.00. The company’s shares closed last Monday at $5.25.

According to TipRanks.com, Chatterjee is a top 100 analyst with an average return of 53.2% and a 76.0% success rate. Chatterjee covers the Healthcare sector, focusing on stocks such as Contineum Therapeutics, Inc. Class A, Sagimet Biosciences, Inc. Class A, and Sionna Therapeutics, Inc. ;'>

AbCellera Biologics has an analyst consensus of Strong Buy, with a price target consensus of $8.75, a 59.7% upside from current levels. In a report issued on May 5, Cantor Fitzgerald also initiated coverage with a Buy rating on the stock with a $7.00 price target.

Read More on WST:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).